bêta
IA Trial Radar
L'essai clinique NCT07114991 pour Obesity &Amp; Overweight, Sedentary Behaviors, Risque cardiométabolique, Inactivité physique est actif, pas en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

E-Bike Commuting and Health in Overweight College Students

Actif, pas en recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT07114991 est un essai interventionnel pour Obesity &Amp; Overweight, Sedentary Behaviors, Risque cardiométabolique, Inactivité physique. Son statut actuel est : actif, pas en recrutement. L'étude a débuté le 1 mai 2025 et vise à recruter 60 participants. Dirigé par University of Wisconsin, River Falls, l'essai devrait être terminé d'ici le 30 juin 2026. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 11 août 2025.
Résumé succinct
This study will evaluate the effects of using a pedal-assist electric bicycle (e-bike) for commuting on physical activity, fitness, and health in overweight or obese college students. Participants will be randomly assigned to either a 12-week e-bike commuting intervention or a control group. The study will measure changes in cardiorespiratory fitness, body composition, blood biomarkers, physical activity, and psychological well-being over a 24-week period.
Description détaillée
This randomized controlled trial investigates the effectiveness of e-bike commuting as a strategy to improve cardiometabolic health, physical activity levels, and psychological well-being in college students with a body mass index (BMI) of 25 kg/m² or higher. Eligible participants will be randomized to either a 12-week e-bike intervention group or a control group that continues usual commuting habits. Assessments will occur at baseline (Week 0), post-intervention (Week 12), and follow-up (Week 24). Each assessment will include VO₂peak testing using a graded cycle ergometer protocol, body composition assessment via BodPod, fasting fingerstick blood tests for glucose, cholesterol, and triglycerides, blood pressure and resting heart rate measurement, and self-report questionnaires evaluating motivation, stress, affect, mental health, and academic engagement. Participants will also complete a 30-minute submaximal cycling test during which affective responses will be recorded, and physical activity will be tracked over 7 days. Those assigned to the intervention group will receive a pedal-assist e-bike, helmet, and safety training and will be asked to ride at least four days per week for 12 weeks. The study aims to determine whether e-bike commuting can promote sustained physical activity and improve cardiometabolic and mental health outcomes in a population at risk for early health decline.
Titre officiel

Effects of Pedal-Assist E-Bike Commuting on Cardiometabolic Health, Physical Activity, and Psychological Well-Being in Overweight College Students

Conditions
Obesity &Amp; OverweightSedentary BehaviorsRisque cardiométaboliqueInactivité physique
Publications
Articles scientifiques et travaux de recherche publiés sur cet essai clinique:
Autres identifiants de l'essai
  • 2025-101
Numéro NCT
Date de début (réel)
2025-05-01
Dernière mise à jour publiée
2025-08-11
Date de fin (estimée)
2026-06-30
Inscription (estimée)
60
Type d'essai
Interventionnel
PHASE
N/A
Statut
Actif, pas en recrutement
Mots clés
Electric bicycle
Active commuting
Exercise motivation
Health behavior
Physical activity
Overweight
Objectif principal
Recherche fondamentale
Plan d'attribution
Randomisé
Modèle d'intervention
Parallèle
Masquage
Aucun (ouvert)
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
ExpérimentalExperimental Group
Participants in this group will receive a pedal-assist electric bicycle (e-bike), helmet, safety training, and cycling computer. They will be instructed to use the e-bike for commuting or transportation at least four days per week for 12 weeks. They will also complete assessments at baseline, Week 12, and Week 24, including fitness testing, body composition, blood testing, surveys, and activity monitoring.
E-bike Commuting
Participants in the intervention group will receive a pedal-assist electric bicycle (e-bike), a helmet, safety training, and a cycling computer. They will be asked to use the e-bike for commuting or personal travel at least four times per week for 12 weeks. E-bike usage will be monitored using a Garmin Edge device. Participants will also complete baseline, 12-week, and 24-week assessments including fitness testing, blood tests, body composition, surveys, and wearable activity monitoring.
Aucune interventionControl Group
Participants in the control group will maintain their usual commuting and physical activity habits for the 12-week intervention period. They will complete the same assessments as the intervention group at baseline, Week 12, and Week 24.
N/A
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Change in daily moderate-to-vigorous physical activity (minutes/day)
Physical activity will be measured using a hip-worn ActiGraph GT3X+ accelerometer over 7 consecutive days at baseline, Week 12, and Week 24. The device will be analyzed using validated cut points to determine average daily time spent in moderate-to-vigorous physical activity (MVPA). The primary outcome is the change in MVPA from baseline to Week 24
From enrollment to end of study at 24 weeks.
Change in cardiorespiratory fitness (VO₂peak, mL/kg/min)
Cardiorespiratory fitness will be measured via a graded cycling test using a metabolic cart to determine peak oxygen uptake (VO₂peak). Participants will complete the test at baseline (Week 0), post-intervention (Week 12), and follow-up (Week 24). The primary comparison will be the change in VO₂peak from baseline to Week 12 between the intervention and control groups.
From enrollment to end of study at 24 weeks.
Critère secondaire d'évaluation
Critères d'évaluationDescription de critèresPériode
Change in body fat percentage
Body composition will be assessed using air displacement plethysmography (BodPod®). Percent body fat will be calculated at baseline, Week 12, and Week 24.
From enrollment to end of study at 24 weeks.
Change in total cholesterol, HDL-C, LDL-C, and triglycerides (mg/dL)
Fasting lipid profiles will be assessed at baseline, Week 12, and Week 24 via fingerstick blood sample. Changes in total cholesterol, HDL, LDL, and triglycerides will be evaluated to assess cardiometabolic risk.
From enrollment to end of study at 24 weeks.
Change in fasting blood glucose (mg/dL)
Fasting blood glucose will be collected via fingerstick and analyzed using a portable blood analyzer. Values will be compared between baseline, Week 12, and Week 24 to determine the impact of the e-bike intervention on glucose regulation.
From enrollment to end of study at 24 weeks.
Change in exercise motivation (BREQ-3 score)
Exercise motivation will be assessed using the Behavioral Regulation in Exercise Questionnaire-3 (BREQ-3) at all three time points. Subscale scores (e.g., intrinsic motivation, external regulation) will be analyzed for changes between baseline, Week 12, and Week 24.
From enrollment to end of study at 24 weeks.
Critères d'éligibilité

Âges éligibles
Adulte
Âge minimum
18 Years
Sexes éligibles
Tous
Accepte les volontaires en bonne santé
Oui
  • Aged 18-29 years
  • Currently enrolled undergraduate or graduate student
  • Body mass index (BMI) ≥25.0 kg/m² (classified as overweight or obese)
  • Self-report of engaging in <150 minutes per week of moderate-to-vigorous physical activity
  • Able and willing to safely ride a bicycle for commuting or transportation purposes
  • Willing to be randomized and complete all study procedures across 24 weeks Able to provide informed consent

  • Current use of a bicycle or e-bike for commuting ≥2 times per week
  • Known cardiovascular, metabolic, or orthopedic conditions that limit physical activity or make exercise testing unsafe
  • Currently pregnant, planning pregnancy during the study period, or less than 6 months postpartum
  • Use of medications known to affect glucose metabolism, heart rate, or physical activity (e.g., beta-blockers, insulin)
  • Diagnosed severe mental health disorders that would impair study participation
  • Participation in another clinical trial or lifestyle intervention within the past 3 months
  • Inability or unwillingness to attend lab visits or comply with the intervention protocol
University of Wisconsin, River Falls logoUniversity of Wisconsin, River Falls
Partie responsable de l'essai
Gregory Ruegsegger, Investigateur principal, Professor, University of Wisconsin, River Falls
Aucune donnée de contact disponible
1 Centres de l'essai dans 1 pays

Wisconsin

University of Wisconsin-River Falls, River Falls, Wisconsin, 54022, United States